Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Credible oncology updates at your fingertips.

Free. No ads. No bias.

Enter our monthly Prize Giveaway!
Earn an entry each time you watch a full Sound Bites video. It's that easy.

Browse Clinical Trial Updates

All
Breast Cancer
CNS Malignancies
Conference Updates
Diagnostics
GI Cancers
GU Cancers
GYN Oncology
Hematologic Malignancies
Lung Cancer
Skin Cancer
Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)

Recognizing HU Resistance: When to Switch

John Mascarenhas, MD
Hematologic Malignancies
Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)

Iberdomide SE profile : Managing Neutropenia While Maximizing Outcomes

Hematologic Malignancies
Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)

MDT approach for patients on 1L ami subQ + laz

Lung Cancer
Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)

EXCALIBER-RRMM Highlights

Hematologic Malignancies
Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

Event free survival with ropeginterferon

Hematologic Malignancies
Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

AML evolving role of application

Hematologic Malignancies

Why subscribe?

  • Get one-minute, non-promotional, educational videos from distinguished thought leaders
  • Tailored to topics you select
    • Breast Cancer
    • Lung Cancer
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecologic Cancers
    • Hemotologic Malignancies
    • Conference updates and more
  • No spam. No ads. No apps to download.
  • Always free and you can opt-out anytime if you feel this isn’t for you.

Fill out the form above to subscribe!

Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Intended for USA healthcare providers only.

If your institution is not listed, please input the Institution / Company name in the field below.

By clicking Subscribe, I agree that I have read and understand IDEOlogy Health’s Privacy Policy and Terms and Conditions and further agree to receive information from IDEOlogy Health and its companies

ideology-health
Inc. 5000

IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.